Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 111-120 , Summer 2009

Current Trends in Radiologic Management of Malignant Pleural Mesothelioma

References 

  1. Kawashima A, Libshitz HI. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol. 1990;155:965–969
  2. Metintas M, Ucgun I, Elbek O, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol. 2002;41:1–9
  3. Patz EF, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol. 1992;159:961–966
  4. Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET. Radiographics. 2004;24:105–119
  5. Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med. 2006;260:517–529
  6. Armato SG, Oxnard GR, MacMahon H, et al. Measurement of mesothelioma on thoracic CT scans: A comparison of manual and computer-assisted techniques. Med Phys. 2004;31:1105–1115
  7. Armato SG, Oxnard GR, Kocherginsky M, et al. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005;12:1301–1309
  8. Armato SG, Ogarek JL, Starkey A, et al. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006;186:1000–1006
  9. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998;115:310–317, discussion, 317-318
  10. Heilo A, Stenwig AE, Solheim OP. Malignant pleural mesothelioma: US-guided histologic core-needle biopsy. Radiology. 1999;211:657–659
  11. Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: Comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–1047
  12. Hatabu H, Tadamura E, Levin DL, et al. Quantitative assessment of pulmonary perfusion with dynamic contrast-enhanced MRI. Magn Reson Med. 1999;42:1033–1038
  13. Hatabu H, Gaa J, Kim D, et al. Pulmonary perfusion: Qualitative assessment with dynamic contrast-enhanced MRI using ultra-short TE and inversion recovery turbo FLASH. Magn Reson Med. 1996;36:503–508
  14. Giesel FL, Choyke PL, Mehndiratta A, et al. Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Acad Radiol. 2008;15:563–570
  15. Gill RR, Gerbaudo VH, Jacobson FL, et al. MR imaging of benign and malignant pleural disease. MRI Clin North Am. 2008;16:319–339:x
  16. Yamamuro M, Gerbaudo VH, Gill RR, et al. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007;64:356–366
  17. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, et al. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: Comparison with histopathology. J Nucl Med. 2002;43:1144–1149
  18. Benard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–722
  19. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, et al. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax. 2003;58:1077–1082
  20. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–1379
  21. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507
  22. Mamede M, Abreu ELP, Oliva MR, et al. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: Correlation with histopathology results. Am J Clin Oncol. 2007;30:377–388
  23. Gerbaudo VH, Julius B. Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol. 2007;64:401–405
  24. Britz-Cunningham SH, Millstine JW, Gerbaudo VH. Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum. Clin Nucl Med. 2008;33:681–687
  25. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005;129:1364–1370
  26. Shen KR, Wain JC, Wright CD, et al. Postpneumonectomy syndrome: Surgical management and long-term results. J Thorac Cardiovasc Surg. 2008;135:1210–1216, discussion, 1216-1219
  27. Gerbaudo V, Mamede M, Trottman-Dickinson B, et al. PET/CT patterns of treatment failure of malignant pleural mesothelioma. [abstract] J Nucl Med. 2007;48:360
  28. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2006;132:763–768
  29. Giesel FL, Bischoff H, Von Tengg-Kobligk H, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: A feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006;129:1570–1576
  30. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587–4593

 HH is supported by NIH grant 5R21CA116271-02.

PII: S1043-0679(09)00075-6

doi: 10.1053/j.semtcvs.2009.06.011

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 111-120 , Summer 2009

Article Tools

* Image Usage & Resolution